Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

Ipsen: Standalone strategy for Somatuline US + companion product for Dysport in LatAm

NEUTRAL, Fair Value EUR33 (-3%)

Published last January Tuesday 14, 2014

Moderna Therapeutics (Not covered): The new year begins with another huge deal!

Published last January Tuesday 14, 2014

Actelion reports stronger-than-expected switch from Tracleer into Opsumit in NRx in the US

BUY, Fair Value CHF75 (-6%)

Published last January Tuesday 14, 2014

Qiagen: Qiagen and Exosome to develop potential game changer companion diagnostics

BUY, Fair Value EUR19,5 (+10%)

Published last January Monday 13, 2014

SAP: Premiminary FY13 results roughly in line, despite some pluses and minuses

BUY, Fair Value EUR74 (+21%)

Published last January Monday 13, 2014

Sanofi: Genzyme expands collaboration with Alnylam

BUY, Fair Value EUR88,5 (+20%)

Published last January Monday 13, 2014

Bureau Veritas: Update: No longer risky

BUY, Fair Value EUR28 (+34%)

Published last January Monday 13, 2014

Infosys' Q3 FY14 results: FY14 revised upwards, positive read-across

Published last January Friday 10, 2014

The Swatch Group: FY 2013 sales grew 8.3%, globally in line with consensus

BUY, Fair Value CHF672 vs. CHF650 (+22%)

Published last January Friday 10, 2014

Bayer: Official offer of Bayer on Algeta

BUY, Fair Value EUR98 (0%)

Published last December Thursday 19, 2013

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities